Does Melatonin Restore Sleep Architecture in Autistic Children

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2018-06-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Although behavioral disorders origins in autistic children are still unclear, they seem to be influenced by sleep disorders. Results of studies performed on sleep quality in autistic children showed a high prevalence of sleep disorders in these children, estimated between 50 and 80% compared to children with typical development and insomnia is one of the sleep disorders most frequently reported by autistic children's parents. Others studies showed circadian rhythm disorder in autistic children which could be the consequence of genetic abnormalities in the melatonin synthesis and the melatonin role in the synaptic transmission modulation.

Melatonin by its sedative effects and its action on circadian pacemaker is a promoter of sleep proposed for insomnia treatment and circadian rhythm disorders.

Two major recent studies (not yet published) in the United States and in England seek to show the effectiveness of melatonin by testing the effects of three doses of melatonin on reducing sleep disorders.

It is therefore interesting and important to conduct a parallel study to assess the melatonin effect not only on the reduction of sleep disorders (sleep onset latency, total sleep time…), but on sleep quality (number of nocturnal awakenings).

The strength of this study lies in the combination of several measurement tools to assess the melatonin dose-effect on all parameters in both physiological (actimetrics, polysomnography), biological (dosage 24h sulfatoxymelatonin), behavioral (sleep questionnaire, index of insomnia severity, rating scale autistic disorder) as well as possible side effects.

The primary objective is to determine the most effective dose of melatonin to improve sleep quality in autistic children.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Melatonin and Sleep Spindles in Autism

NCT05716906

Autism Spectrum Disorder

ACTIVE_NOT_RECRUITING NA

Melatonin for Sleep in Children With Autism

NCT00927030

Autistic Disorder Insomnia

COMPLETED PHASE1

Iron Treatment of Sleep Disorders in Children With Autism Spectrum Disorder

NCT01745497

Autism Spectrum Disorder Insomnia

COMPLETED PHASE2

Pilot Study of Sleep Therapy and Biomarkers in Children With Autism Spectrum Disorders

NCT02487082

Autism Spectrum Disorder

TERMINATED PHASE2

Targeting Insomnia in School Aged Children With Autism Spectrum Disorder

NCT04545606

Insomnia Chronic Autism Spectrum Disorder

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sleep Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

melatonin 0.5mg

Group Type ACTIVE_COMPARATOR

melatonin

Intervention Type DRUG

one capsule, melatonin 0.5 mg, oral, once a day, 30 minutes before bedtime

melatonin 2mg

Group Type ACTIVE_COMPARATOR

Melatonin

Intervention Type DRUG

one capsule, melatonin 2 mg, oral, once a day, 30 minutes before bedtime

melatonin 6mg

Group Type ACTIVE_COMPARATOR

Melatonin

Intervention Type DRUG

one capsule, melatonin 6 mg, oral, once a day, 30 minutes before bedtime

placebo

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

one capsule, placebo, oral, once a day, 30 minutes before bedtime

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

melatonin

one capsule, melatonin 0.5 mg, oral, once a day, 30 minutes before bedtime

Intervention Type DRUG

Melatonin

one capsule, melatonin 2 mg, oral, once a day, 30 minutes before bedtime

Intervention Type DRUG

Melatonin

one capsule, melatonin 6 mg, oral, once a day, 30 minutes before bedtime

Intervention Type DRUG

placebo

one capsule, placebo, oral, once a day, 30 minutes before bedtime

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Boys and girls from 3 to 12 years old with autism spectrum,
* Diagnosed by psychiatrists according to the diagnostic criteria for autism ICD-10 AND ADI or ADOS positive,
* With trouble sleeping, assessed by questionnaire CHSQ,
* Having made a night polysomnography,
* Written informed consent (signed by parents),
* Affiliated with the French universal healthcare system.

Exclusion Criteria

* Children who stopped all treatment for sleep for less than one month,
* Liver or kidney insufficiencies,
* Acute illness during or occurred in the month preceding the study,
* Neurological disease without autism spectrum , patients with non-controlled epilepsy
* Health background witch can influence sleep (other than autism itself),
* Obstructive syndrome (history - oral breathing in wakefulness, nocturnal snoring significant (heard the door closed), nocturnal respiratory effort, apnea reported by parents- and clinical examination (chronic nasal congestion, large tonsils and touching),
* Known hypersensitivity to the active substance or to one of the excipient contained in the verum or in the placebo,
* Children under treatment against-indicated with the study treatment witch can't be stopped

Minimum Eligible Age

3 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No